Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-05-21

Nano-X Imaging Ltd.

Nanox develops digital tomosynthesis imaging systems and sells related AI, cloud, teleradiology, marketplace, and healthcare IT services to providers.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A financing-gated shot at imaging utility scale

The opportunity is real because the company already owns a cleared device plus workflow assets, but the rerating needs proof that signed channels become live recurring-revenue sites. This is a high-variance growth story where financing and site activation matter more than partnership headlines.

Analysis

Thesis

Nanox is a distressed but real option on turning FDA-cleared low-cost imaging hardware plus AI, teleradiology, and Health IT into a managed imaging utility; if financing and activation gates clear, a tiny revenue base can compound non-linearly as each live site carries multiple attached revenue streams.

Last Economy Alignment

Cheaper AI helps Nanox bundle imaging, workflow, and remote reading into a fuller service, but it does not own the deepest choke point and still faces capital, regulatory, and OEM-bundling pressure.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

8.0x (from 5 most recent analyses)

Reasoning

The upside case is not about winning as a pure hardware company. It is about proving that live sites become recurring revenue nodes with service, workflow, and AI attached. If that happens, investors can value the business less like a distressed medtech experiment and more like a modestly recurring imaging stack. I still keep the rerating below premium software names because financing risk, regulation, and hardware exposure remain real.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is mainly a sequence-risk story. Nanox first needs enough liquidity, then smoother outsourced manufacturing, then faster site activation, and finally proof that active sites carry attractive attach from services and software. The business has real optionality because the current EV is depressed, but the same low starting point reflects genuine risks around dilution, delayed commercialization, and incumbent imaging vendors that can bundle hardware, service, financing, and workflow more easily.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company filing or press release appeared in the last 7-10 days, so the market is still trading on the April 20 business update and April 30 20-F.
The share price remains near the lower end of the 52-week range, keeping market cap near distressed levels and making financing terms highly consequential.
There is still no fresh public proof that the recent U.S. channel agreements have already translated into a disclosed step-up in activated revenue-producing sites.

Forecast update

The upside math improved mainly because the starting enterprise value is lower, while the core commercialization logic is largely unchanged.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.27

They control a cleared imaging device and a small but useful workflow stack, so cheaper AI can help them sell a fuller service bundle around each scan. The risk is that bigger incumbents can bundle faster, while cash needs and site approvals still decide whether Nanox's flywheel ever really starts.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$6.00

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research